UCSF Multiple Sclerosis Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cree, Bruce
IMPACT MS, NCT04466150: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Active, not recruiting
4
30
US
Ocrelizumab, Ocrevus
University of California, San Francisco, Genentech, Inc., Valhalla Foundation
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
12/26
07/27
NCT06451159: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Recruiting
1
10
US
KYV-101 (Biological) - 0.33 ×10^8 cells, CAR T-cell therapy, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
Bruce Cree, Kyverna Therapeutics
Progressive Multiple Sclerosis
06/26
06/27
Green, Ari J
ReCOVER, NCT02521311 / 2018-001756-35: Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis

Recruiting
2
90
US
Clemastine, Tavist, Clemastine fumarate, Walhist, Placebo
University of California, San Francisco, Moorfields Eye Hospital NHS Foundation Trust
Optic Neuritis
08/26
08/26
ReVIVE, NCT05359653: Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Recruiting
1/2
74
US
Clemastine Fumarate, Clemastine, Dayhist, Dayhist Allergy, Placebo, Sugar pill
University of California, San Francisco, United States Department of Defense
Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
06/25
06/25
ReINFORCE, NCT06065670: Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Not yet recruiting
1/2
44
US
Clemastine Fumarate, Clemastine, Dayhist, Dayhist Allergy, Placebo, Sugar pill
University of California, San Francisco
Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
10/26
10/26
Gelfand, Jeffrey
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting
1/2
10
US
NRTX-1001, GABA-secreting interneurons
Neurona Therapeutics
Epilepsy, Temporal Lobe
07/26
07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26
MS-BIOME, NCT03594487: Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
1
30
US
FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
Jeffrey Gelfand
Relapsing Remitting Multiple Sclerosis
08/24
08/24

Download Options